WO2024097889A2 - Systems and methods for verifying iboga alkaloid treatment using temporospatial connectivity - Google Patents

Systems and methods for verifying iboga alkaloid treatment using temporospatial connectivity Download PDF

Info

Publication number
WO2024097889A2
WO2024097889A2 PCT/US2023/078533 US2023078533W WO2024097889A2 WO 2024097889 A2 WO2024097889 A2 WO 2024097889A2 US 2023078533 W US2023078533 W US 2023078533W WO 2024097889 A2 WO2024097889 A2 WO 2024097889A2
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
brain
imaging data
lagged
post
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/078533
Other languages
French (fr)
Other versions
WO2024097889A3 (en
Inventor
Nolan R. Williams
Anish MITRA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority to US19/127,014 priority Critical patent/US20260166052A1/en
Publication of WO2024097889A2 publication Critical patent/WO2024097889A2/en
Publication of WO2024097889A3 publication Critical patent/WO2024097889A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00—Image analysis
    • G06T7/0002—Inspection of images, e.g. flaw detection
    • G06T7/0012—Biomedical image inspection
    • G06T7/0014—Biomedical image inspection using an image reference approach
    • G06T7/0016—Biomedical image inspection using an image reference approach involving temporal comparison
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H30/00—ICT specially adapted for the handling or processing of medical images
    • G16H30/40—ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00—Indexing scheme for image analysis or image enhancement
    • G06T2207/10—Image acquisition modality
    • G06T2207/10072—Tomographic images
    • G06T2207/10088—Magnetic resonance imaging [MRI]
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00—Indexing scheme for image analysis or image enhancement
    • G06T2207/30—Subject of image; Context of image processing
    • G06T2207/30004—Biomedical image processing
    • G06T2207/30016—Brain

Definitions

  • the present invention generally relates to the empirical identification of certain types of depression, generation of personalized neurostimulation targets based on temporospatial analysis of brain activation to treat said types of depression, and confirmation of effective treatment.
  • a connectome is a comprehensive map of neural connections in the brain.
  • Connectomics is a science that comprises of two broad fields, structural connectivity and functional connectivity.
  • Structural connectivity considers the neuron to neuron connectivity in the brain and uses this information to define network architectures.
  • functional connectivity is built on communication between neurons and/or neuronal ensembles, and defines networks on the basis of mutual communication defined using metrics such as temporal correlation.
  • a number of functional networks which are typically shared amongst all humans are known such as (but not limited to) the default mode network, the salience network, the attention network, any many more.
  • Brain activity can be non-invasively measured using any of a number of functional neuroimaging techniques including (but not limited to), positron emission tomography (PET), functional magnetic resonance imaging (fMRI), functional nearinfrared spectroscopy (fN IRS), and functional ultrasound imaging (fUS).
  • functional neuroimaging techniques including (but not limited to), positron emission tomography (PET), functional magnetic resonance imaging (fMRI), functional nearinfrared spectroscopy (fN IRS), and functional ultrasound imaging (fUS).
  • One embodiment includes a treatment verification system, including a processor, and a memory containing a treatment verification application that configures the processor to obtain a pre-treatment functional imaging data of a patient’s brain, identify pre-treatment disordered lagged correlations between different brain regions associated with a neuropsychiatric disorder using the functional imaging data, treat the patient with an iboga alkaloid or salt thereof in an amount to achieve a physiologic effect, obtain a post-treatment functional imaging data of the patient’s brain, identify reversion of the pre-treatment disordered lagged correlations in the post-treatment functional imaging data, and provide a verification that treatment with the iboga alkaloid or salt thereof provided a therapeutic effect in treating the neuropsychiatric condition.
  • the neuropsychiatric condition is major depressive disorder.
  • the neuropsychiatric condition is suicidal ideation.
  • the iboga alkaloid or salt thereof is provided with a cardioprotective agent.
  • the treatment verification application further configures the processor to label voxels in the pre-treatment functional brain imaging data that make up a dorsolateral prefrontal cortex and an anterior cingulate cortex in the pre-treatment functional brain imaging data using a brain atlas, generate a whole-brain lagged correlation map using the voxels labelled as making up the anterior cingulate cortex as a reference region, where the whole-brain lagged correlation map includes a peak correlation magnitude and a peak temporal delay, compute a lag for all pairs of voxels containing grey matter, and assemble the computed lags into a time-delay matrix.
  • the treatment verification application further configures the processor to compute the mean delay over all columns of the time-delay matrix to produce a lag projection map.
  • the treatment verification application further configures the processor to label voxels in the post-treatment functional brain imaging data that make up a dorsolateral prefrontal cortex and an anterior cingulate cortex in the pre-treatment functional brain imaging data using a brain atlas, generate a whole-brain lagged correlation map using the voxels labelled as making up the anterior cingulate cortex as a reference region, where the whole-brain lagged correlation map includes a peak correlation magnitude and a peak temporal delay, compute a lag for all pairs of voxels containing grey matter, and assemble the computed lags into a time-delay matrix.
  • the treatment verification application further configures the processor to compute the mean delay over all columns of the time-delay matrix to produce a lag projection map.
  • pre-treatment functional imaging data and posttreatment functional imaging data are produced using a magnetic resonance imaging machine.
  • the post-treatment functional imaging data is obtained between 1 day and 1 month post-treatment.
  • One embodiment includes a method of verifying treatment with iboga alkaloids, including obtaining a pre-treatment functional imaging data of a patient’s brain, identifying pre-treatment disordered lagged correlations between different brain regions associated with a neuropsychiatric disorder using the functional imaging data, treating the patient with an iboga alkaloid or salt thereof in an amount to achieve a physiologic effect, obtaining a post-treatment functional imaging data of the patient’s brain, identifying reversion of the pre-treatment disordered lagged correlations in the post-treatment functional imaging data, and providing a verification that treatment with the iboga alkaloid or salt thereof provided a therapeutic effect in treating the neuropsychiatric condition.
  • the neuropsychiatric condition is major depressive disorder.
  • the neuropsychiatric condition is suicidal ideation.
  • the iboga alkaloid or salt thereof is provided with a cardioprotective agent.
  • identifying pre-treatment disordered lagged correlation includes labeling voxels in the pre-treatment functional brain imaging data that make up a dorsolateral prefrontal cortex and an anterior cingulate cortex in the pre-treatment functional brain imaging data using a brain atlas, generating a whole-brain lagged correlation map using the voxels labelled as making up the anterior cingulate cortex as a reference region, where the whole-brain lagged correlation map includes a peak correlation magnitude and a peak temporal delay, computing a lag for all pairs of voxels containing grey matter, and assembling the computed lags into a time-delay matrix.
  • the treatment verification application further configures the processor to compute the mean delay over all columns of the time-delay matrix to produce a lag projection map.
  • identifying post-treatment disordered lagged correlation includes labeling voxels in the post-treatment functional brain imaging data that make up a dorsolateral prefrontal cortex and an anterior cingulate cortex in the pre-treatment functional brain imaging data using a brain atlas, generating a whole-brain lagged correlation map using the voxels labelled as making up the anterior cingulate cortex as a reference region, where the whole-brain lagged correlation map includes a peak correlation magnitude and a peak temporal delay, computing a lag for all pairs of voxels containing grey matter, and assembling the computed lags into a time-delay matrix.
  • identifying post-treatment disordered lagged correlations further includes computing the mean delay over all columns of the time-delay matrix to produce a lag projection map.
  • pre-treatment functional imaging data and post-treatment functional imaging data are produced using a magnetic resonance imaging machine.
  • the post-treatment functional imaging data is obtained between 1 day and 1 month post-treatment.
  • FIG. 1 is a system diagram for a treatment verification system in accordance with an embodiment of the invention.
  • FIG. 2 is a block diagram for a treatment verifier in accordance with an embodiment of the invention.
  • FIG. 3 is a flow chart for a treatment verification in accordance with an embodiment of the invention.
  • FIG. 4 is a flow chart for a treatment verification process for computing activation lag in accordance with an embodiment of the invention.
  • FIG. 5A-D is a set of charts illustrating computation of functional lag and a target in accordance with an embodiment of the invention.
  • FIG. 6 is a series of brain images showing example differences in temporal changes in activation over time between high responders and low responders in accordance with an embodiment of the invention.
  • Depression is a debilitating mental condition that occurs with relatively high frequency in the population. Many forms of clinical depression are the result of pathological brain circuitry. Multiple different brain circuitry abnormalities can give rise to depression.
  • MDD major depressive disorder
  • a mechanism-based biomarker for MDD has remained elusive.
  • most studies have focused on either tonic activity levels in a given brain region or interactions between brain regions on the basis of zero-lag correlation magnitude (“functional connectivity”).
  • functional connectivity zero-lag correlation magnitude
  • the limitation of this conventional view of connectivity is that there is no assignment of signaling directionality. Thus, a circumstance in which brain region A signals to brain region B can appear identical to a circumstance in which the direction of communication is reversed, even though the neurobiological implications of communication direction may be profound.
  • Systems and methods described herein instead take a spatiotemporal view of connectivity, where lag times in activation between different correlated brain structures are measured in order to derive directionality of activation.
  • a particular type of depression is left dorsolateral prefrontal cortex (L-DLPFC)-anterior cingulate cortex (ACC) based major depressive disorder (MDD), where the depression arises from dysregulation of at least these two brain regions.
  • L-DLPFC left dorsolateral prefrontal cortex
  • ACC anterior cingulate cortex
  • MDD major depressive disorder
  • activation irregularly flows from the ACC to the DLPFC i.e. ACC activation leads correlated DLPFC activation.
  • Many other mental conditions may arise from similar irregular activation patterns systems and methods described herein utilize the temporal activation arrangement of various structures within the brain to diagnose MDD.
  • pathological temporal arrangements provide objective biomarkers for diagnoses of many forms of MDD.
  • Certain treatments described herein can be used to treat MDD and other neuropsychiatric conditions, and when the treatment is efficacious, the pathological temporal activation pattern reverts to a healthy temporal activation pattern. Verification of treatment efficacy can be objectively determined by confirming the shift to healthy temporal arrangement post-stimulation. While the below focuses particularly on L-DLPFC - ACC based MDD, as can be readily appreciated, different pathological brain circuities may be associated with other classes of depression, or other neurological conditions. As such, similar approaches can be used with respect to different brain structures relevant to said other neurological conditions without departing from the scope or spirit of the invention.
  • pathological temporal activation patterns can be changed into healthy temporal activation patterns via treatment with iboga alkaloids.
  • Iboga alkaloid treatments are discussed in U.S. Patent Application No. 18/467,343, filed September 14, 2023, titled “Methods of Treatment with an Iboga Alkaloid”, the disclosure of which is hereby incorporated by reference in its entirety. Treatment verification systems are discussed in further detail below.
  • Treatment verification systems obtain functional brain imaging data before and after treatment in order to determine objectively whether or not the treatment has worked.
  • treatment verification systems as described herein can provide an objective indication of whether or not a particular treatment is appropriate for a given patient based on the pre-treatment functional brain imaging data.
  • neurostimulation targeting systems identify whether or not a given patient has a neurological condition which can be identified via spatiotemporal connectivity analysis, and/or whether or not they are likely to be a responder to various treatments such as, but not limited to, treatment with iboga alkaloids .
  • System 100 includes a functional brain imaging device 110.
  • Functional brain imaging devices are capable of imaging a patient’s brain and recording a time-series of activation at different locations in the patient’s brain.
  • the functional brain imaging device an fMRI machine, but any number of different functional brain imaging modalities can be used as appropriate to the requirements of specific applications of embodiments of the invention.
  • System 100 further includes a treatment verifier 120.
  • Treatment verifiers receive functional brain imaging data pre- and post-treatment and verify treatment based on spatiotemporal activation patterns within the functional brain imaging data.
  • the treatment verifier identifies whether or not a patient has a neurological condition marked by abnormal spatiotemporal activation patterns.
  • Treatment verifiers can determine whether or not an individual is likely to be a responder to neurostimulation. In various embodiments, conditions that are not marked by abnormal spatiotemporal activation patterns are unlikely to respond to neurostimulation. However particular abnormal spatiotemporal activation patterns may also indicate a non-responsive patient.
  • the functional brain imaging device and the treatment verifier communicate over network 130.
  • Networks can be made up of multiple networks or direct connections that are wired or wireless.
  • components of the system are not directly networked and instead data is passed between components via a physically transferred machine-readable medium.
  • treatment verifiers operate on their own without the need for direct connection with functional brain imaging devices.
  • Treatment verifier 200 has a processor 210.
  • Processors can be a central processing unit (CPU), a graphics processing unit (GPU), an applicationspecific integrated circuit (ASIC), field-programable gate array (FPGA), and/or any other logic circuity as appropriate to the requirements of specific applications of embodiments of the invention.
  • treatment verifiers have more than one processor.
  • the treatment verifier 200 further includes an input/output (I/O) interface 220.
  • I/O interfaces can communicate via wired and/or wireless modalities to other devices such as (but not limited to) neurostimulators, functional brain imaging devices, displays, and/or any other electronic device as appropriate to the requirements of specific applications of embodiments of the invention.
  • Treatment verifier 200 additionally contains a memory 230.
  • Memory 230 can be made of volatile memory, nonvolatile memory, and/or any combination thereof.
  • Memory 230 contains a target generation application 232 and is capable of storing functional imaging data 234.
  • treatment verification applications configure the processor to use received functional imaging data of a patient’s brain to select a treatment protocol based on the patient’s specific activation pattern.
  • treatment verification applications can configure the processor to determine if a patient will be a responder to treatment with iboga alkaloids. While a particular architecture for a treatment verifier is shown, any number of different computing architectures can be used without departing from the scope or spirit of the invention. Processes for treatment verification are discussed in further detail below.
  • Process 300 includes obtaining (310) functional imaging data of a patient’s brain prior to treatment.
  • the functional imaging data is fMRI data containing blood oxygen level dependent (BOLD) signals for different voxels representing different brain regions.
  • BOLD blood oxygen level dependent
  • similar BOLD signals can be obtained using any of a variety of different modalities, and further similar temporal measurement of brain activation can be used as appropriate to the requirements of specific applications of embodiments of the invention.
  • Regions of interest are labeled (320) such that each voxel is assigned to a particular brain structure.
  • labeling is achieved using a brain atlas.
  • pre-treatment activation lag is computed (330).
  • the activation lag imputes a direction of signal flow within the brain.
  • the activation lag is spatiotemporal, reflecting which connected portions of the brain are active at which time relative to each other.
  • the pre-treatment activation lag is matched (340) to a particular treatment such as (but not limited to) treatment using iboga alkaloids previously identified as being effective in reversing pathological temporal activation patterns.
  • a post-treatment functional imaging data is obtained (360) in a similar manner as described above.
  • the same regions of interest are labeled (370) in the post-treatment functional imaging data, and a post-treatment activation lag profile is calculated (380). If the pathological temporal activation pattern seen in the pre-treatment activation lag profile is modified and/or reversed in the posttreatment activation lag profile, treatment efficacy is verified (390).
  • post-treatment functional imaging data can be obtained multiple times at different time points after treatment (or during ongoing treatment) in order to confirm continuing efficacy and/or the point at which treatment has taken effect.
  • the specific point at which post-treatment functional imaging data is taken can be modified based on the expected time for the treatment to take effect, which can be anywhere from hours to weeks.
  • Process 400 includes obtaining (410) functional imaging data.
  • the functional imaging data is a resting state fMRI (rs-fMRI).
  • the functional imaging data is labeled (420).
  • the DLPFC and ACC are identified using segmentation of structural MRI scans, and/or any other structural scan.
  • lagged correlations in the BOLD signal are computed (430) to generate a whole-brain lagged correlation map.
  • An example BOLD signal for the DLPFC and the ACC are illustrated in FIG. 5A.
  • the lagged correlation map includes two main parameters: peak correlation magnitude, and peak temporal delay.
  • first lags for all pairs of voxels in gray matter in the functional imaging data are computed.
  • An example crosscorrelation function for the time series in FIG. 5A is illustrated in FIG. 5B.
  • yellow markers and the black line depict empirically measured cross correlation.
  • the green curve depicts a parabolic interpolation about the peak, with the orange marker at the interpolated peak showing a temporal offset of approximately 0.6 sec.
  • TD matrices represent the lag between all pairs of voxels in gray matter.
  • the mean over all columns of the TD matrix is computed to yield a lag projection map.
  • Lag projection maps topographically represent the mean lag between each voxel and the rest of the brain.
  • the TD matrix format and an example lag projection map are illustrated in FIG. 5C.
  • the region of the DLPFC most strongly anticorrelated with the ACC is identified (440).
  • a threshold-based clustering on peak correlation magnitude can be applied to isolate the most strongly anticorrelated region after accounting for signaling delay.
  • the region of the DLPFC which abnormally receives signals from the ACC is identified (450), i.e. the region of the DLPFC which lags the ACC.
  • the overlap between the two identified DLPFC regions represents the intersection of the peak anti-correlation magnitude with the ACC and the abnormal directed signal receivers in the DLPFC.
  • An example overlapping area of the two identified regions is illustrated in FIG. 5D.
  • the specific regions may be different for different conditions, however similar processing steps can be applied to identify targets for other conditions as appropriate to the requirements of specific applications of embodiments of the invention.
  • Using the identified brain activation whether or not a patient is a good candidate for treatment using an iboga alkaloid is determined (460).
  • FIG. 6 shows baseline differences in ACC latency structure between high responders and low responders to iboga alkaloid treatment. If similar latency patterns are present in a given patient, it may suggest that they are less likely to respond, or may respond to a lesser degree than would otherwise be expected.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • General Physics & Mathematics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Social Psychology (AREA)
  • Theoretical Computer Science (AREA)
  • Quality & Reliability (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Systems and methods for verifying iboga alkaloid treatment using temporospatial connectivity in accordance with embodiments of the invention are illustrated. One embodiment includes a treatment verification system, including a processor, and a memory containing a treatment verification application that configures the processor to obtain a pre-treatment functional imaging data of a patient's brain, identify pre-treatment disordered lagged correlations between different brain regions associated with a neuropsychiatric disorder using the functional imaging data, treat the patient with an iboga alkaloid or salt thereof in an amount to achieve a physiologic effect, obtain a post-treatment functional imaging data of the patient's brain, identify reversion of the pre-treatment disordered lagged correlations in the post-treatment functional imaging data, and provide a verification that treatment with the iboga alkaloid or salt thereof provided a therapeutic effect in treating the neuropsychiatric condition.

Description

Systems and Methods for Verifying Iboga Alkaloid Treatment using Temporospatial Connectivity
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The current application claims the benefit of and priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 63/382,079 entitled “Systems and Methods for Neurostimulation Targeting using Temporospatial Connectivity” filed November 2, 2022. The disclosure of U.S. Provisional Patent Application No. 63/382,079 is hereby incorporated by reference in their entireties for all purposes.
FIELD OF THE INVENTION
[0002] The present invention generally relates to the empirical identification of certain types of depression, generation of personalized neurostimulation targets based on temporospatial analysis of brain activation to treat said types of depression, and confirmation of effective treatment.
BACKGROUND
[0003] A connectome is a comprehensive map of neural connections in the brain. Connectomics is a science that comprises of two broad fields, structural connectivity and functional connectivity. Structural connectivity considers the neuron to neuron connectivity in the brain and uses this information to define network architectures. In contrast, functional connectivity is built on communication between neurons and/or neuronal ensembles, and defines networks on the basis of mutual communication defined using metrics such as temporal correlation. A number of functional networks which are typically shared amongst all humans are known such as (but not limited to) the default mode network, the salience network, the attention network, any many more.
[0004] Brain activity can be non-invasively measured using any of a number of functional neuroimaging techniques including (but not limited to), positron emission tomography (PET), functional magnetic resonance imaging (fMRI), functional nearinfrared spectroscopy (fN IRS), and functional ultrasound imaging (fUS). SUMMARY OF THE INVENTION
[0005] Systems and methods for verifying iboga alkaloid treatment using temporospatial connectivity in accordance with embodiments of the invention are illustrated. One embodiment includes a treatment verification system, including a processor, and a memory containing a treatment verification application that configures the processor to obtain a pre-treatment functional imaging data of a patient’s brain, identify pre-treatment disordered lagged correlations between different brain regions associated with a neuropsychiatric disorder using the functional imaging data, treat the patient with an iboga alkaloid or salt thereof in an amount to achieve a physiologic effect, obtain a post-treatment functional imaging data of the patient’s brain, identify reversion of the pre-treatment disordered lagged correlations in the post-treatment functional imaging data, and provide a verification that treatment with the iboga alkaloid or salt thereof provided a therapeutic effect in treating the neuropsychiatric condition.
[0006] In a further embodiment, the neuropsychiatric condition is major depressive disorder.
[0007] In still another embodiment, the neuropsychiatric condition is suicidal ideation. [0008] In a still further embodiment, the iboga alkaloid or salt thereof is provided with a cardioprotective agent.
[0009] In yet another embodiment, to identify pre-treatment disordered lagged correlation, the treatment verification application further configures the processor to label voxels in the pre-treatment functional brain imaging data that make up a dorsolateral prefrontal cortex and an anterior cingulate cortex in the pre-treatment functional brain imaging data using a brain atlas, generate a whole-brain lagged correlation map using the voxels labelled as making up the anterior cingulate cortex as a reference region, where the whole-brain lagged correlation map includes a peak correlation magnitude and a peak temporal delay, compute a lag for all pairs of voxels containing grey matter, and assemble the computed lags into a time-delay matrix.
[0010] In a yet further embodiment, to identify pre-treatment disordered lagged correlations, the treatment verification application further configures the processor to compute the mean delay over all columns of the time-delay matrix to produce a lag projection map. [0011] In another additional embodiment, to identify post-treatment disordered lagged correlation, the treatment verification application further configures the processor to label voxels in the post-treatment functional brain imaging data that make up a dorsolateral prefrontal cortex and an anterior cingulate cortex in the pre-treatment functional brain imaging data using a brain atlas, generate a whole-brain lagged correlation map using the voxels labelled as making up the anterior cingulate cortex as a reference region, where the whole-brain lagged correlation map includes a peak correlation magnitude and a peak temporal delay, compute a lag for all pairs of voxels containing grey matter, and assemble the computed lags into a time-delay matrix.
[0012] In a further additional embodiment, to identify post-treatment disordered lagged correlations, the treatment verification application further configures the processor to compute the mean delay over all columns of the time-delay matrix to produce a lag projection map.
[0013] In another embodiment again, pre-treatment functional imaging data and posttreatment functional imaging data are produced using a magnetic resonance imaging machine.
[0014] In a further embodiment again, the post-treatment functional imaging data is obtained between 1 day and 1 month post-treatment.
[0015] One embodiment includes a method of verifying treatment with iboga alkaloids, including obtaining a pre-treatment functional imaging data of a patient’s brain, identifying pre-treatment disordered lagged correlations between different brain regions associated with a neuropsychiatric disorder using the functional imaging data, treating the patient with an iboga alkaloid or salt thereof in an amount to achieve a physiologic effect, obtaining a post-treatment functional imaging data of the patient’s brain, identifying reversion of the pre-treatment disordered lagged correlations in the post-treatment functional imaging data, and providing a verification that treatment with the iboga alkaloid or salt thereof provided a therapeutic effect in treating the neuropsychiatric condition.
[0016] In still yet another embodiment, the neuropsychiatric condition is major depressive disorder.
[0017] In a still yet further embodiment, the neuropsychiatric condition is suicidal ideation. [0018] In still another additional embodiment, the iboga alkaloid or salt thereof is provided with a cardioprotective agent.
[0019] In a still further additional embodiment, identifying pre-treatment disordered lagged correlation includes labeling voxels in the pre-treatment functional brain imaging data that make up a dorsolateral prefrontal cortex and an anterior cingulate cortex in the pre-treatment functional brain imaging data using a brain atlas, generating a whole-brain lagged correlation map using the voxels labelled as making up the anterior cingulate cortex as a reference region, where the whole-brain lagged correlation map includes a peak correlation magnitude and a peak temporal delay, computing a lag for all pairs of voxels containing grey matter, and assembling the computed lags into a time-delay matrix.
[0020] In still another embodiment again, to identify pre-treatment disordered lagged correlations, the treatment verification application further configures the processor to compute the mean delay over all columns of the time-delay matrix to produce a lag projection map.
[0021] In a still further embodiment again, identifying post-treatment disordered lagged correlation includes labeling voxels in the post-treatment functional brain imaging data that make up a dorsolateral prefrontal cortex and an anterior cingulate cortex in the pre-treatment functional brain imaging data using a brain atlas, generating a whole-brain lagged correlation map using the voxels labelled as making up the anterior cingulate cortex as a reference region, where the whole-brain lagged correlation map includes a peak correlation magnitude and a peak temporal delay, computing a lag for all pairs of voxels containing grey matter, and assembling the computed lags into a time-delay matrix.
[0022] In yet another additional embodiment, identifying post-treatment disordered lagged correlations further includes computing the mean delay over all columns of the time-delay matrix to produce a lag projection map.
[0023] In a yet further additional embodiment, pre-treatment functional imaging data and post-treatment functional imaging data are produced using a magnetic resonance imaging machine. [0024] In yet another embodiment again, the post-treatment functional imaging data is obtained between 1 day and 1 month post-treatment.
[0025] Additional embodiments and features are set forth in part in the description that follows, and in part will become apparent to those skilled in the art upon examination of the specification or may be learned by the practice of the invention. A further understanding of the nature and advantages of the present invention may be realized by reference to the remaining portions of the specification and the drawings, which forms a part of this disclosure.
BRIEF DESCRIPTION OF THE DRAWINGS
[0026] The description and claims will be more fully understood with reference to the following figures and data graphs, which are presented as exemplary embodiments of the invention and should not be construed as a complete recitation of the scope of the invention.
[0027] FIG. 1 is a system diagram for a treatment verification system in accordance with an embodiment of the invention.
[0028] FIG. 2 is a block diagram for a treatment verifier in accordance with an embodiment of the invention.
[0029] FIG. 3 is a flow chart for a treatment verification in accordance with an embodiment of the invention.
[0030] FIG. 4 is a flow chart for a treatment verification process for computing activation lag in accordance with an embodiment of the invention.
[0031] FIG. 5A-D is a set of charts illustrating computation of functional lag and a target in accordance with an embodiment of the invention.
[0032] FIG. 6 is a series of brain images showing example differences in temporal changes in activation over time between high responders and low responders in accordance with an embodiment of the invention.
DETAILED DESCRIPTION
[0033] Depression is a debilitating mental condition that occurs with relatively high frequency in the population. Many forms of clinical depression are the result of pathological brain circuitry. Multiple different brain circuitry abnormalities can give rise to depression. Studies have suggested that major depressive disorder (MDD) is likely caused by aberrant communication patterns in brain-wide networks. However, a mechanism-based biomarker for MDD has remained elusive. Traditionally, most studies have focused on either tonic activity levels in a given brain region or interactions between brain regions on the basis of zero-lag correlation magnitude (“functional connectivity”). The limitation of this conventional view of connectivity is that there is no assignment of signaling directionality. Thus, a circumstance in which brain region A signals to brain region B can appear identical to a circumstance in which the direction of communication is reversed, even though the neurobiological implications of communication direction may be profound.
[0034] Systems and methods described herein instead take a spatiotemporal view of connectivity, where lag times in activation between different correlated brain structures are measured in order to derive directionality of activation. For example, a particular type of depression is left dorsolateral prefrontal cortex (L-DLPFC)-anterior cingulate cortex (ACC) based major depressive disorder (MDD), where the depression arises from dysregulation of at least these two brain regions. In particular activation irregularly flows from the ACC to the DLPFC (i.e. ACC activation leads correlated DLPFC activation). Many other mental conditions may arise from similar irregular activation patterns systems and methods described herein utilize the temporal activation arrangement of various structures within the brain to diagnose MDD.
[0035] Further, these pathological temporal arrangements provide objective biomarkers for diagnoses of many forms of MDD. Certain treatments described herein can be used to treat MDD and other neuropsychiatric conditions, and when the treatment is efficacious, the pathological temporal activation pattern reverts to a healthy temporal activation pattern. Verification of treatment efficacy can be objectively determined by confirming the shift to healthy temporal arrangement post-stimulation. While the below focuses particularly on L-DLPFC - ACC based MDD, as can be readily appreciated, different pathological brain circuities may be associated with other classes of depression, or other neurological conditions. As such, similar approaches can be used with respect to different brain structures relevant to said other neurological conditions without departing from the scope or spirit of the invention.
[0036] In particular, in numerous embodiments, pathological temporal activation patterns can be changed into healthy temporal activation patterns via treatment with iboga alkaloids. Iboga alkaloid treatments are discussed in U.S. Patent Application No. 18/467,343, filed September 14, 2023, titled “Methods of Treatment with an Iboga Alkaloid”, the disclosure of which is hereby incorporated by reference in its entirety. Treatment verification systems are discussed in further detail below.
Treatment Verification Systems
[0037] Treatment verification systems obtain functional brain imaging data before and after treatment in order to determine objectively whether or not the treatment has worked. In numerous embodiments, treatment verification systems as described herein can provide an objective indication of whether or not a particular treatment is appropriate for a given patient based on the pre-treatment functional brain imaging data. In many embodiments, neurostimulation targeting systems identify whether or not a given patient has a neurological condition which can be identified via spatiotemporal connectivity analysis, and/or whether or not they are likely to be a responder to various treatments such as, but not limited to, treatment with iboga alkaloids .
[0038] Turning now to FIG. 1 , a treatment verification system in accordance with an embodiment of the invention is illustrated. System 100 includes a functional brain imaging device 110. Functional brain imaging devices are capable of imaging a patient’s brain and recording a time-series of activation at different locations in the patient’s brain. In numerous embodiments, the functional brain imaging device an fMRI machine, but any number of different functional brain imaging modalities can be used as appropriate to the requirements of specific applications of embodiments of the invention.
[0039] System 100 further includes a treatment verifier 120. Treatment verifiers receive functional brain imaging data pre- and post-treatment and verify treatment based on spatiotemporal activation patterns within the functional brain imaging data. In many embodiments, the treatment verifier identifies whether or not a patient has a neurological condition marked by abnormal spatiotemporal activation patterns. Treatment verifiers can determine whether or not an individual is likely to be a responder to neurostimulation. In various embodiments, conditions that are not marked by abnormal spatiotemporal activation patterns are unlikely to respond to neurostimulation. However particular abnormal spatiotemporal activation patterns may also indicate a non-responsive patient. [0040] The functional brain imaging device and the treatment verifier communicate over network 130. Networks can be made up of multiple networks or direct connections that are wired or wireless. In various embodiments, components of the system are not directly networked and instead data is passed between components via a physically transferred machine-readable medium. In various embodiments, treatment verifiers operate on their own without the need for direct connection with functional brain imaging devices.
[0041] Turning now to FIG. 2, a treatment verifier in accordance with an embodiment of the invention is illustrated. Treatment verifier 200 has a processor 210. Processors can be a central processing unit (CPU), a graphics processing unit (GPU), an applicationspecific integrated circuit (ASIC), field-programable gate array (FPGA), and/or any other logic circuity as appropriate to the requirements of specific applications of embodiments of the invention. In various embodiments, treatment verifiers have more than one processor.
[0042] The treatment verifier 200 further includes an input/output (I/O) interface 220. I/O interfaces can communicate via wired and/or wireless modalities to other devices such as (but not limited to) neurostimulators, functional brain imaging devices, displays, and/or any other electronic device as appropriate to the requirements of specific applications of embodiments of the invention.
[0043] Treatment verifier 200 additionally contains a memory 230. Memory 230 can be made of volatile memory, nonvolatile memory, and/or any combination thereof. Memory 230 contains a target generation application 232 and is capable of storing functional imaging data 234. In many embodiments, treatment verification applications configure the processor to use received functional imaging data of a patient’s brain to select a treatment protocol based on the patient’s specific activation pattern. In various embodiments, treatment verification applications can configure the processor to determine if a patient will be a responder to treatment with iboga alkaloids. While a particular architecture for a treatment verifier is shown, any number of different computing architectures can be used without departing from the scope or spirit of the invention. Processes for treatment verification are discussed in further detail below.
Treatment Verification
[0044] Treatments as contemplated herein are selected based on activation time in correlated brain structures such that treatment is intended to reverse the direction of activation in order to treat a neurological condition. Turning now to FIG. 3, a flow chart for verifying effective treatment using activation time as a biomarker in accordance with an embodiment of the invention is illustrated. Process 300 includes obtaining (310) functional imaging data of a patient’s brain prior to treatment. In many embodiments, the functional imaging data is fMRI data containing blood oxygen level dependent (BOLD) signals for different voxels representing different brain regions. However, similar BOLD signals can be obtained using any of a variety of different modalities, and further similar temporal measurement of brain activation can be used as appropriate to the requirements of specific applications of embodiments of the invention.
[0045] Regions of interest are labeled (320) such that each voxel is assigned to a particular brain structure. In many embodiments, labeling is achieved using a brain atlas. Based on activation over time between correlated regions of interest, pre-treatment activation lag is computed (330). In many embodiments, the activation lag imputes a direction of signal flow within the brain. In this way, the activation lag is spatiotemporal, reflecting which connected portions of the brain are active at which time relative to each other. In numerous embodiments, the pre-treatment activation lag is matched (340) to a particular treatment such as (but not limited to) treatment using iboga alkaloids previously identified as being effective in reversing pathological temporal activation patterns.
[0046] The patient is then treated (350). A post-treatment functional imaging data is obtained (360) in a similar manner as described above. The same regions of interest are labeled (370) in the post-treatment functional imaging data, and a post-treatment activation lag profile is calculated (380). If the pathological temporal activation pattern seen in the pre-treatment activation lag profile is modified and/or reversed in the posttreatment activation lag profile, treatment efficacy is verified (390). As can be readily appreciated, post-treatment functional imaging data can be obtained multiple times at different time points after treatment (or during ongoing treatment) in order to confirm continuing efficacy and/or the point at which treatment has taken effect. Similarly, the specific point at which post-treatment functional imaging data is taken can be modified based on the expected time for the treatment to take effect, which can be anywhere from hours to weeks.
[0047] Turning now to FIG. 4, a similar process for verifying iboga alkaloids as a viable pharmaceutical treatment modality for MDD accordance with an embodiment of the invention is illustrated. Process 400 includes obtaining (410) functional imaging data. In many embodiments, the functional imaging data is a resting state fMRI (rs-fMRI). Within the functional imaging data, the dorsolateral prefrontal cortex (DLPFC) and the anterior cingulate cortex (ACC) are labeled (420). In many embodiments, the DLPFC and ACC are identified using segmentation of structural MRI scans, and/or any other structural scan. Using the anatomical cingulate area as a reference region, lagged correlations in the BOLD signal are computed (430) to generate a whole-brain lagged correlation map. An example BOLD signal for the DLPFC and the ACC are illustrated in FIG. 5A. The lagged correlation map includes two main parameters: peak correlation magnitude, and peak temporal delay.
[0048] In many embodiments, to calculate lagged correlations, first lags for all pairs of voxels in gray matter in the functional imaging data are computed. An example crosscorrelation function for the time series in FIG. 5A is illustrated in FIG. 5B. In the illustrated embodiment, yellow markers and the black line depict empirically measured cross correlation. The green curve depicts a parabolic interpolation about the peak, with the orange marker at the interpolated peak showing a temporal offset of approximately 0.6 sec.
[0049] These results are assembled into time-delay (TD) matrices, which have dimensions voxels x voxels and entries in units of seconds. TD matrices represent the lag between all pairs of voxels in gray matter. The mean over all columns of the TD matrix is computed to yield a lag projection map. Lag projection maps topographically represent the mean lag between each voxel and the rest of the brain. The TD matrix format and an example lag projection map are illustrated in FIG. 5C. [0050] The region of the DLPFC most strongly anticorrelated with the ACC is identified (440). In many embodiments, a threshold-based clustering on peak correlation magnitude can be applied to isolate the most strongly anticorrelated region after accounting for signaling delay. The region of the DLPFC which abnormally receives signals from the ACC is identified (450), i.e. the region of the DLPFC which lags the ACC.
[0051] The overlap between the two identified DLPFC regions represents the intersection of the peak anti-correlation magnitude with the ACC and the abnormal directed signal receivers in the DLPFC. An example overlapping area of the two identified regions is illustrated in FIG. 5D.
[0052] As noted above, the specific regions may be different for different conditions, however similar processing steps can be applied to identify targets for other conditions as appropriate to the requirements of specific applications of embodiments of the invention. Using the identified brain activation, whether or not a patient is a good candidate for treatment using an iboga alkaloid is determined (460). FIG. 6 shows baseline differences in ACC latency structure between high responders and low responders to iboga alkaloid treatment. If similar latency patterns are present in a given patient, it may suggest that they are less likely to respond, or may respond to a lesser degree than would otherwise be expected.
[0053] Although systems and methods for treatment verification are discussed above, many different architectures and methods can be implemented in accordance with many different embodiments of the invention which utilize spatiotemporal connectivity in a similar manner. It is therefore to be understood that the present invention may be practiced in ways other than specifically described, without departing from the scope and spirit of the present invention. Thus, embodiments of the present invention should be considered in all respects as illustrative and not restrictive. Accordingly, the scope of the invention should be determined not by the embodiments illustrated, but by the appended claims and their equivalents.

Claims

WHAT IS CLAIMED IS:
1 . A treatment verification system, comprising: a processor; and a memory containing a treatment verification application that configures the processor to: obtain a pre-treatment functional imaging data of a patient’s brain; identify pre-treatment disordered lagged correlations between different brain regions associated with a neuropsychiatric disorder using the functional imaging data; treat the patient with an iboga alkaloid or salt thereof in an amount to achieve a physiologic effect; obtain a post-treatment functional imaging data of the patient’s brain; identify reversion of the pre-treatment disordered lagged correlations in the post-treatment functional imaging data; and provide a verification that treatment with the iboga alkaloid or salt thereof provided a therapeutic effect in treating the neuropsychiatric condition.
2. The treatment verification system of claim 1 , wherein the neuropsychiatric condition is major depressive disorder.
3. The treatment verification system of claim 1 , wherein the neuropsychiatric condition is suicidal ideation.
4. The treatment verification system of claim 1 , wherein the iboga alkaloid or salt thereof is provided with a cardioprotective agent.
5. The treatment verification system of claim 1 , wherein to identify pre-treatment disordered lagged correlation, the treatment verification application further configures the processor to: label voxels in the pre-treatment functional brain imaging data that make up a dorsolateral prefrontal cortex and an anterior cingulate cortex in the pre-treatment functional brain imaging data using a brain atlas; generate a whole-brain lagged correlation map using the voxels labelled as making up the anterior cingulate cortex as a reference region, where the whole-brain lagged correlation map comprises a peak correlation magnitude and a peak temporal delay; compute a lag for all pairs of voxels containing grey matter; and assemble the computed lags into a time-delay matrix.
6. The treatment verification system of claim 5, wherein to identify pre-treatment disordered lagged correlations, the treatment verification application further configures the processor to compute the mean delay over all columns of the time-delay matrix to produce a lag projection map.
7. The treatment verification system of claim 1 , wherein to identify post-treatment disordered lagged correlation, the treatment verification application further configures the processor to: label voxels in the post-treatment functional brain imaging data that make up a dorsolateral prefrontal cortex and an anterior cingulate cortex in the pre-treatment functional brain imaging data using a brain atlas; generate a whole-brain lagged correlation map using the voxels labelled as making up the anterior cingulate cortex as a reference region, where the whole-brain lagged correlation map comprises a peak correlation magnitude and a peak temporal delay; compute a lag for all pairs of voxels containing grey matter; and assemble the computed lags into a time-delay matrix.
8. The treatment verification system of claim 7, wherein to identify post-treatment disordered lagged correlations, the treatment verification application further configures the processor to compute the mean delay over all columns of the time-delay matrix to produce a lag projection map.
9. The treatment verification system of claim 1 , wherein pre-treatment functional imaging data and post-treatment functional imaging data are produced using a magnetic resonance imaging machine.
10. The treatment verification system of claim 1 , wherein the post-treatment functional imaging data is obtained between 1 day and 1 month post-treatment.
11. A method of verifying treatment with iboga alkaloids, comprising: obtaining a pre-treatment functional imaging data of a patient’s brain; identifying pre-treatment disordered lagged correlations between different brain regions associated with a neuropsychiatric disorder using the functional imaging data; treating the patient with an iboga alkaloid or salt thereof in an amount to achieve a physiologic effect; obtaining a post-treatment functional imaging data of the patient’s brain; identifying reversion of the pre-treatment disordered lagged correlations in the post-treatment functional imaging data; and providing a verification that treatment with the iboga alkaloid or salt thereof provided a therapeutic effect in treating the neuropsychiatric condition.
12. The method of verifying treatment with iboga alkaloids of claim 11 , wherein the neuropsychiatric condition is major depressive disorder.
13. The method of verifying treatment with iboga alkaloids of claim 11 , wherein the neuropsychiatric condition is suicidal ideation.
1 . The method of verifying treatment with iboga alkaloids of claim 11 , wherein the iboga alkaloid or salt thereof is provided with a cardioprotective agent.
15. The method of verifying treatment with iboga alkaloids of claim 11 , wherein identifying pre-treatment disordered lagged correlation comprises: labeling voxels in the pre-treatment functional brain imaging data that make up a dorsolateral prefrontal cortex and an anterior cingulate cortex in the pre-treatment functional brain imaging data using a brain atlas; generating a whole-brain lagged correlation map using the voxels labelled as making up the anterior cingulate cortex as a reference region, where the whole-brain lagged correlation map comprises a peak correlation magnitude and a peak temporal delay; computing a lag for all pairs of voxels containing grey matter; and assembling the computed lags into a time-delay matrix.
16. The method of verifying treatment with iboga alkaloids of claim 15, wherein to identify pre-treatment disordered lagged correlations, the treatment verification application further configures the processor to compute the mean delay over all columns of the time-delay matrix to produce a lag projection map.
17. The method of verifying treatment with iboga alkaloids of claim 11 , wherein identifying post-treatment disordered lagged correlation comprises: labeling voxels in the post-treatment functional brain imaging data that make up a dorsolateral prefrontal cortex and an anterior cingulate cortex in the pre-treatment functional brain imaging data using a brain atlas; generating a whole-brain lagged correlation map using the voxels labelled as making up the anterior cingulate cortex as a reference region, where the whole-brain lagged correlation map comprises a peak correlation magnitude and a peak temporal delay; computing a lag for all pairs of voxels containing grey matter; and assembling the computed lags into a time-delay matrix.
18. The method of verifying treatment with iboga alkaloids of claim 17, wherein identifying post-treatment disordered lagged correlations further comprises computing the mean delay over all columns of the time-delay matrix to produce a lag projection map.
19. The method of verifying treatment with iboga alkaloids of claim 11 , wherein pretreatment functional imaging data and post-treatment functional imaging data are produced using a magnetic resonance imaging machine.
20. The method of verifying treatment with iboga alkaloids of claim 11 , wherein the post-treatment functional imaging data is obtained between 1 day and 1 month posttreatment.
PCT/US2023/078533 2022-11-02 2023-11-02 Systems and methods for verifying iboga alkaloid treatment using temporospatial connectivity Ceased WO2024097889A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US19/127,014 US20260166052A1 (en) 2022-11-02 2023-11-02 Systems and Methods for Verifying Iboga Alkaloid Treatment using Temporospatial Connectivity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263382079P 2022-11-02 2022-11-02
US63/382,079 2022-11-02

Publications (2)

Publication Number Publication Date
WO2024097889A2 true WO2024097889A2 (en) 2024-05-10
WO2024097889A3 WO2024097889A3 (en) 2024-07-18

Family

ID=90931628

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/078533 Ceased WO2024097889A2 (en) 2022-11-02 2023-11-02 Systems and methods for verifying iboga alkaloid treatment using temporospatial connectivity

Country Status (2)

Country Link
US (1) US20260166052A1 (en)
WO (1) WO2024097889A2 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12616706B2 (en) * 2019-03-07 2026-05-05 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
WO2020227646A1 (en) * 2019-05-09 2020-11-12 Apkarian Technologies Llc Methods and compositions for treating pain
CA3144385A1 (en) * 2019-06-24 2020-12-30 Caamtech, Inc. Ibogaine formulations
GB2636959B (en) * 2020-10-12 2025-12-24 Univ Leland Stanford Junior Systems and methods for targeted neuromodulation

Also Published As

Publication number Publication date
US20260166052A1 (en) 2026-06-18
WO2024097889A3 (en) 2024-07-18

Similar Documents

Publication Publication Date Title
Hansen et al. Integrating brainstem and cortical functional architectures
US20230210388A1 (en) Systems and Methods for Predicting and Treating Neurological Condition Relapses
Stiso et al. White matter network architecture guides direct electrical stimulation through optimal state transitions
Barksdale et al. Low-intensity transcranial focused ultrasound amygdala neuromodulation: a double-blind sham-controlled target engagement study and unblinded single-arm clinical trial
Staffaroni et al. A longitudinal characterization of perfusion in the aging brain and associations with cognition and neural structure
Wong et al. Loneliness in late-life depression: structural and functional connectivity during affective processing
Kleckner et al. Evidence for a large-scale brain system supporting allostasis and interoception in humans
Ramirez-Mahaluf et al. Subgenual anterior cingulate cortex controls sadness-induced modulations of cognitive and emotional network hubs
Amianto et al. Intrinsic connectivity networks within cerebellum and beyond in eating disorders
Kühn et al. Reduced thickness of anterior cingulate cortex in obsessive-compulsive disorder
Suñol et al. Differential patterns of brain activation between hoarding disorder and obsessive-compulsive disorder during executive performance
Fang et al. Personalizing repetitive transcranial magnetic stimulation for precision depression treatment based on functional brain network controllability and optimal control analysis
JP2024526229A (en) Target identification method, apparatus, electronic device, storage medium and neuromodulation device
JP2024528514A (en) Target identification method, apparatus, electronic device, storage medium and neuromodulation device
Kirino et al. Simultaneous fMRI-EEG-DTI recording of MMN in patients with schizophrenia
McMackin et al. Dysfunction of attention switching networks in amyotrophic lateral sclerosis
AU2021362169A1 (en) Systems and methods for targeted neuromodulation
Doucet et al. Gray matter abnormalities in temporal lobe epilepsy: relationships with resting-state functional connectivity and episodic memory performance
Sun et al. Precision network modeling of transcranial magnetic stimulation across individuals suggests therapeutic targets and potential for improvement
Cañete-Massé et al. Abnormal degree centrality and functional connectivity in Down syndrome: A resting-state fMRI study
Abe et al. Neurobiological mechanisms of electroconvulsive therapy for depression: Insights into hippocampal volumetric increases from clinical and preclinical studies
Bossus et al. Causal connectivity maps derived from single-pulse interleaved TMS/fMRI
Hadi et al. Balance recovery and its link to vestibular agnosia in traumatic brain injury: a longitudinal behavioural and neuro-imaging study
Caria et al. Neuroanatomical predictors of real‐time fMRI‐based anterior insula regulation. A supervised machine learning study
Tan et al. Effects of repetitive transcranial magnetic stimulation on individual variability of resting-state functional connectivity in major depressive disorder

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23887015

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23887015

Country of ref document: EP

Kind code of ref document: A2